Search Results | Blood | American Society of Hematology

1-20 of 48

2 3

Sort by

Sort Order Select

Journal Articles

Splenic Irradiation Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with Myelofibrosis

John R Bales, Haesook T Kim, Roxana Portillo, Chirayu Patel, Steven McAfee, Bimalangshu Dey, Thomas Spitzer, Yi-Bin Chen, Areej El-Jawahri, Zachariah Defilipp, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12957–12958.

DOI: https://doi.org/10.1182/blood-2022-162478

Published: 2022

Journal Articles

Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Matthew L Chase, Reed E. Drews, Alfred I Lee, Erin G Reid, Aaron T. Gerds, Gabriela S. Hobbs, Leslie R Ellis, Marc S Zumberg, Jonathan Berry, Jason A Freed

Blood (2022) 140 (Supplement 1): 10781–10783.

DOI: https://doi.org/10.1182/blood-2022-159990

Published: 2022

Journal Articles

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Ross Baker, Jana Baskar, Brett Charlton, Gabriela S. Hobbs, Wolfgang Jarolimek, Sung-Eun Lee, Lucia Masarova, Anne-Marie Watson

Blood (2022) 140 (Supplement 1): 3947–3948.

DOI: https://doi.org/10.1182/blood-2022-158344

Published: 2022

Journal Articles

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Kevin C. Miller, Jennifer Lombardi Story, Julia Foster, Jenna A. Moran, Amir T. Fathi, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12295–12296.

DOI: https://doi.org/10.1182/blood-2022-170986

Published: 2022

Journal Articles

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Chi-Joan How, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12284–12285.

DOI: https://doi.org/10.1182/blood-2022-157076

Published: 2022

Journal Articles

Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Orly Leiva, Emaad Siddiqui, Gabriela S. Hobbs, Sripal Bangalore

Blood (2022) 140 (Supplement 1): 9729–9730.

DOI: https://doi.org/10.1182/blood-2022-157476

Published: 2022

Journal Articles

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Katelin Katsis, Eva Elder, Donna S. Neuberg, Patrick M. Reeves, Marcela V. Maus, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6852–6853.

DOI: https://doi.org/10.1182/blood-2022-157628

Published: 2022

Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2022) 140 (Supplement 1): 579–582.

DOI: https://doi.org/10.1182/blood-2022-160384

Published: 2022

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

DOI: https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2022) 140 (Supplement 1): 3309–3311.

DOI: https://doi.org/10.1182/blood-2022-160100

Published: 2022

Journal Articles

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Orly Leiva, Chi-Joan How, Andrew M. Brunner, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6808–6809.

DOI: https://doi.org/10.1182/blood-2022-170607

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

DOI: https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-139661

Published: 2020

Journal Articles

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Areej El-Jawahri, MD, Thomas W. Leblanc, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Vicki Jackson, MD, Toby Campbell, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Ellin Gafford, MD, Jillian Gustin, MD, Bhavana Bhatnagar, DO, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Showly Nicholson, BS, Debra Davis, Jennifer S. Temel

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-138883

Published: 2020

Journal Articles

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-141643

Published: 2020

Journal Articles

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-140176

Published: 2020

Journal Articles

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Dagny M. Vaughn, MS, P. Connor Johnson, MD, Annemarie D. Jagielo, BA, Matthew J. Reynolds, BA, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Bhavana Bhatnagar, DO, Thomas W. LeBlanc, MDMA,MS, Areej El-Jawahri, MD

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-139777

Published: 2020

Journal Articles

Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk

Orly Leiva, MD, Olesya Baker, PhD, Andrew M. Brunner, Hanny Al-Samkari, MD, Rebecca Karp Leaf, MD, Rachel P. Rosovsky, MD MPH, Amir T. Fathi, MD, James I Weitzman, MD, Larissa Bornikova, MD, Valentina Nardi, MD, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 14.

DOI: https://doi.org/10.1182/blood-2020-137311

Published: 2020

Journal Articles

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

Joan How, MD, Yiwen Liu, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Katya Ravid, PhD DSc, Wolfgang Jarolimek, Brett Charlton, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 16.

DOI: https://doi.org/10.1182/blood-2020-139223

Published: 2020

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-140584

Published: 2020

2 3

NARROW

Splenic Irradiation Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with Myelofibrosis

Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2 -Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only